Proposal for Clinical Classification of Cutaneous Manifestations in Covid-19 and in Post Vaccination Against Sars-Cov-2: An Observational Study

被引:0
|
作者
Liberato Rostey, Renato Roberto [1 ,2 ]
Fernandes Fontes, Cor Jesus [1 ,2 ]
机构
[1] Univ Fed Mato Grosso, Cuiaba, Brazil
[2] Univ Fed Mato Grosso, Julio Muller Sch Hosp, Cuiaba, Brazil
来源
关键词
COVID-19; Skin Manifestations; SARS-CoV-2; Vaccine; SELF-MEDICATION; DERMATITIS; DISEASES;
D O I
10.5812/archcid-137498
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: This is a clinical evaluation of patients with the incident, acute, or related cutaneous manifestations associated with coronavirus disease 2019 (COVID-19) and/or vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objectives: We aimed to propose a classification of dermatological manifestations related to either COVID-19 or vaccination against SARS-CoV-2. Methods: In an observational descriptive study, a classification of cutaneous manifestations is proposed based on groups of etiological hypotheses, which came from a systematic characterization and record of the observed skin lesions of patients who were evaluated personally and via teleconsultation from July 2020 to July 2022 in two reference dermatology services located in the state of Mato Grosso, Brazil. Results: A total of 108 patients were included. Eighty-six patients (79.6%) had incident, acute, or COVID-19-related skin manifestations, 15 (13.9%) had dermatological lesions exclusively after vaccination against SARS-CoV-2, and seven (6.5%) %) had cutaneous manifestations related to both COVID-19 and the vaccine. A total of 143 different dermatological manifestations were diagnosed, for which different etiological hypotheses were established based on the clinical and evolutionary characteristics of the lesion, the use of concomitant medications, and the temporal link with COVID-19 and/or the vaccine against SARS-CoV-2. The observed skin manifestations were classified as peri-infectious and post-infectious immune-inflammatory reactions related to COVID-19 (62.2%); exacerbation, by COVID-19, of pre-existing skin diseases in the patient (4.2%); skin manifestations resulting from the socio-sanitary context of the pandemic (2.1%); adverse drug reactions from the treatment of COVID-19 (14%); and adverse skin reactions from SARS-CoV-2 vaccines (17.5%). Conclusions: The proposed clinical classification may assist physicians who are faced with dermatological lesions associated with COVID-19 or after active immunization against SARS-CoV-2.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Clinical characteristics of headache after vaccination against COVID-19 (Coronavirus SARS-CoV-2) with the COVID-19 Vaccine BBIBP-CorV: a prospective multicentre observational cohort study
    Goebel, C.
    Heinze, A.
    Karstedt, S.
    Morscheck, M.
    Tashiro, L.
    Cirkel, A.
    Hamid, Q.
    Halwani, R.
    Temsah, M. H.
    Ziemann, M.
    Goerg, S.
    Muente, T.
    Goebel, H.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 76 - 76
  • [22] SARS-CoV-2 viremia and COVID-19 mortality: A prospective observational study
    Giacomelli, Andrea
    Righini, Elena
    Micheli, Valeria
    Pinoli, Pietro
    Bernasconi, Anna
    Rizzo, Alberto
    Oreni, Letizia
    Ridolfo, Anna Lisa
    Antinori, Spinello
    Ceri, Stefano
    Rizzardini, Giuliano
    PLOS ONE, 2023, 18 (04):
  • [23] Clinical characteristics of headache after vaccination against COVID-19 (Coronavirus SARS-CoV-2) with the COVID-19 mRNA-1273 Moderna vaccine: a prospective multicentre observational cohort study
    Goebel, C.
    Heinze, A.
    Karstedt, S.
    Morscheck, M.
    Tashiro, L.
    Cirkel, A.
    Hamid, Q.
    Halwani, R.
    Temsah, M. H.
    Ziemann, M.
    Goerg, S.
    Muente, T.
    Goebel, H.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 81 - 82
  • [24] Clinical characteristics of headache after vaccination against COVID-19 (Coronavirus SARS-CoV-2) with the COVID-19 mRNA-1273 Moderna vaccine: a prospective multicentre observational cohort study
    Gobel, C.
    Heinze, A.
    Karstedt, S.
    Morscheck, M.
    Tashiro, L.
    Cirkel, A.
    Hamid, Q.
    Halwani, R.
    Temsah, M. H.
    Ziemann, M.
    Goerg, S.
    Munte, T.
    Goebel, H.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 54 - 54
  • [25] COVID-19: The Novel and Lethal Culprit The Extrapulmonary Manifestations of SARS-CoV-2 (COVID-19)
    Shah, Syed Zulfiquar Ali
    Devrajani, Bikha Ram
    Lashari, Naveed Aslam
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (06): : 1130 - 1131
  • [26] Vaccine against COVID-19 or against SARS-CoV-2 infection?
    Rieske, Piotr
    ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY, 2020, 7 (03) : 131 - 145
  • [27] Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature
    Matar, S.
    Oules, B.
    Sohier, P.
    Chosidow, O.
    Beylot-Barry, M.
    Dupin, N.
    Aractingi, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (11) : E686 - E689
  • [28] Analysis of SARS-CoV-2 vaccine against COVID-19
    Kazuyori, Taisuke
    Sato, Akihito
    Morimoto, Yasuhiro
    Ito, Akihiko
    Kuwano, Kazuyoshi
    RESPIROLOGY, 2023, 28 : 202 - 203
  • [29] Suggesting Ritonavir against COVID-19/SARS-CoV-2
    Choudhury, Shuvasish
    Mazumder, Muhammed Khairujjaman
    MEDICAL HYPOTHESES, 2020, 140
  • [30] The global battle against SARS-CoV-2 and COVID-19
    Deng, Chu-Xia
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (10): : 1676 - U96